AEterna Zentaris Inc. (NASDAQ:AEZS) reported earnings of ($0.31) per share missing Walls Streets expectations.
AEterna Zentaris Inc. (NASDAQ:AEZS) reported 3/31/2017 earnings this Afternoon, coming in at ($0.31) per share, missing Wall Street’s estimates of ($0.30) per Share. Revenue for the quarter came in at $0.26 million missing the streets estimates of $0.85 million
Analyst Coverage For AEterna Zentaris Inc. (NASDAQ:AEZS)
These are 3 Buy Ratings .
The current consensus rating for AEterna Zentaris Inc. (NASDAQ:AEZS) is Buy (Score: 3.00) with a consensus target price of $5.17 , a potential (474.07% upside)
About Company Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc. Recent Trading for AEterna Zentaris Inc. (NASDAQ:AEZS) Shares of AEterna Zentaris Inc. closed the previous trading session at 0.910 up +0.020 2.25% with 271,458 shares trading hands.
The post AEterna Zentaris Inc. (NASDAQ:AEZS) reported earnings of ($0.31) per share missing Walls Streets expectations. appeared first on Market Exclusive.